The BRCA Exchange: Global Data Sharing and Knowledge Exchange to Enable Accurate Clinical Care
|
|
- Allison Russell
- 5 years ago
- Views:
Transcription
1 The BRCA Exchange: Global Data Sharing and Knowledge Exchange to Enable Accurate Clinical Care Lena Dolman, MSc Manager, Clinical Working Group Manager, Strategy & Outreach Global Alliance for Genomics and Health (GA4GH) CCGenome17 June 29, 2017
2 BRCA variation is relatively common with well known medical implications No single source for BRCA variant information 2107 LOVD 3276 Variants High numbers of VUSs, where classification limited by inability to see all data on a variant ClinVar 7961 Variants UMD 3675 Variants As of May 2016 (UMD last public release (May 2015)) 2 Courtesy of Rachel Liao
3 Goal: To improve the care of patients at risk of breast and ovarian cancer by creating a decentralized, global public repository to assist in the analysis of BRCA1 and BRCA2 1. Share BRCA1 and BRCA2 variants publicly 2. Create an environment for collaborative variant curation with access to evidence (e.g. phenotypes, family history, genetic data, and functional studies) 3. Create a curated list of BRCA variants, interpreted by expert consensus, to enable, without dictating, accurate clinical care 4. Create a model for all genes 3 Courtesy of Rachel Liao
4 Goal: One-Stop Shop for BRCA1/2 Variant Data Courtesy of Faisal Alquaddoomi
5 Public repositories: Each contributes distinct information Combined, BRCA Challenge has aggregated ~19,000 individual deduplicated variants + CIMBA! 5 Courtesy of Rachel Liao
6 Option 1: Expert Reviewed data (>4,900 ENIGMAclassified variants) 6
7 Option 1: Expert Reviewed data 7
8 Option 2: All Public data 8
9 Option 2: All Public data 9
10 Option 2: All Public data 10
11 Coming soon More variants & more ENIGMA classifications More data types for All Public Data portal (e.g. functional assays) Automated curation tools for pre-computing (where possible) Restricted-access tier for case-level data review Your data? 11
12 Research Global Learning for Health Interoperable Data Sharing: APIs Standards Frameworks Interoperable Data Sharing: APIs Standards Frameworks Healthcare 12
13 Acknowledgements Project Manager Rachel Liao, Broad Institute (United States) Steering Committee Sir John Burn, Newcastle University Co-Chair Stephen Chanock, National Cancer Institute Co-Chair Antonis Antoniou, University of Cambridge Larry Brody, National Human Genome Research Institute Robert Cook-Deegan, Duke University Fergus Couch, Mayo Clinic Johan den Dunnen, Leiden University Medical Center Susan Domchek, University of Pennsylvania Douglas Easton, University of Cambridge William Foulkes, McGill University Judy Garber, Dana Farber Cancer Institute David Golgar, Huntsman Cancer Center Kazuto Kato, Osaka University Baroness Delyth Morgan, Breast Cancer Now Robert Nussbaum, Invitae Ken Offit, Memorial Sloan Kettering Cancer Center Sharon Plon, Baylor College of Medicine Nazneen Rahman, Institute of Cancer Research Gunnar Rätsch, ETH Zurich, SIB Heidi Rehm, Harvard Medical School Mark Robson, Memorial Sloan Kettering Cancer Center Wendy Rubinstein, National Institute of Health Amanda Spurdle, QIMR Berghofer Medical Research Institute Dominique Stoppa-Lyonnet, Curie Institute Sean Tavtigian, University of Utah 13
14 Thank you
Conflicts of Interest
This is great information, but how do I use it?: Information needs of genetic counselors related to reclassification of Variants of Uncertain Significance Courtney Scherr, PhD Moffitt Cancer Center Teri
More informationPreventing BRCA-related cancer: A think tank for innovative strategies, milestone objectives and research priorities
BANBURY CENTER REPORTS Preventing BRCA-related cancer: A think tank for innovative strategies, milestone objectives and research priorities Banbury Center, Cold Spring Harbor Laboratory, Cold Spring Harbor,
More informationRecent Advances in Breast and Ovarian Cancer Genetics
2 ND ANNUAL SCIENTIFIC SYMPOSIUM Recent Advances in Breast and Ovarian Cancer Genetics Tuesday, May 6 Wednesday, May 7, 2014 Smilow Center for Translational Research Auditorium/Commons (enter through Perelman
More informationGlobal Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium April 24 th, 2015 The Shilla Jeju Hotel, Jeju Island, Korea
Global Breast Cancer Conference 2015 & 4th International Breast Cancer Symposium April 24 th, 2015 The Shilla Jeju Hotel, Jeju Island, Korea Dr. Steven A. Narod MD, FRCPC Canada Research Chair in Breast
More informationInherited Cancer Genomics and Prevention:
Inherited Cancer Genomics and Prevention: How much cancer risk is inherited? Clinical utility of germline genetic testing in precision prevention and targeted therapy Kenneth Offit MD MPH Chief, Clinical
More informationBRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer
6 TH ANNUAL SCIENTIFIC SYMPOSIUM A CME/CNE Certified Conference BRCA1, BRCA2 and Beyond: An Update on Hereditary Cancer Keynote Speaker and Basser Global Prize Awardee: Professor Ashok Venkitaraman, MBSS,
More informationSpeakers. Text to be added
Speakers SESSION 1 Clinical status and perspectives for hereditary breast and ovarian cancer (HBOC) risk prediction. Fergus Couch Mayo Clinic Cancer Center and the Center for Individualized Medicine, Diana
More informationValue of environmental information and how to gather it
Value of environmental information and how to gather it David Hunter Nuffield Department of Population Health University of Oxford Harvard TH Chan School of Public Health Channing Laboratory, Brigham and
More informationSURVEILLANCE FOR BRCA AND LYNCH SYNDROME: Risk Criteria and Genetic Counseling and Testing Data for Cancer Cases
SURVEILLANCE FOR BRCA AND LYNCH SYNDROME: Risk Criteria and Genetic Counseling and Testing Data for Cancer Cases Carol Sweeney PhD Director, Utah Cancer Registry Supported by CDC UNIVERSITY OF UTAH HEALTH,
More informationRecent Advances in Breast and Ovarian Cancer Genetics
3 rd Annual Scientific Symposium Recent Advances in Breast and Ovarian Cancer Genetics Keynote Speaker and Basser Global Prize Awardee: Mary-Claire King, PhD Monday May 11, 2015 Smilow Center for Translational
More informationCancer risk prediction via algorithms: identifying individuals at high-risk of breast and ovarian cancer
Cancer risk prediction via algorithms: identifying individuals at high-risk of breast and ovarian cancer Antonis C. Antoniou Department of Public Health and Primary Care University of Cambridge, U.K. No
More informationC. H. H. Kerkhofs 1, A. B. Spurdle 2, P. J. Lindsey 1, D. E. Goldgar 3 and E. B. Gómez-García 1*
Kerkhofs et al. Hereditary Cancer in Clinical Practice (2016) 14:10 DOI 10.1186/s13053-016-0050-9 RESEARCH Assessing biases of information contained in pedigrees for the classification of BRCAgenetic variants:
More information4 TH International LFS Association Symposium
4 TH International LFS Association Symposium hosted by The Hospital for Sick Children and in partnership with the LiFE Consortium April 25-29 TH, 2018 Toronto, Ontario Canada CONFERENCE AGENDA WEDNESDAY,
More informationTITLE: Aurora-A as a Modifier of Breast Cancer Risk in BRCA1/2 Mutation Carriers
AD Award Number: W81XWH-04-1-0588 TITLE: Aurora-A as a Modifier of Breast Cancer Risk in BRCA1/2 Mutation Carriers PRINCIPAL INVESTIGATOR: Fergus J. Couch, Ph.D. CONTRACTING ORGANIZATION: Mayo Clinic Rochester,
More informationWe take cancer personally. Basser.org
We take cancer personally. Basser.org BRIEF BOASTS (Top Accomplishments / At a Glance) Before the Center was founded in 2012, there were no targeted therapies for BRCA-related cancers now three drugs have
More informationData sharing in Canada through the COGR:
Data sharing in Canada through the COGR: a unified clinical genome database as a community resource for standardizing and sharing genetic interpretations Dr. Matthew Lebo, Kathleen-Rose Zakoor, Dr. Jordan
More informationConsistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories
original report Consistency of BRCA1 and BRCA2 Variant Classifications Among Clinical Diagnostic Laboratories Stephen E. Lincoln Shan Yang Melissa S. Cline Yuya Kobayashi Can Zhang Scott Topper David Haussler
More informationA Research Program on Rapid Reviews
A Research Program on Rapid Reviews Andrea C. Tricco MSc, PhD Twitter: @ATricco Scientist, Knowledge Translation Program, Li Ka Shing Knowledge Institute of St. Michael s Hospital Co-Director, Queen's
More informationJ Clin Oncol 34: by American Society of Clinical Oncology INTRODUCTION
VOLUME 34 NUMBER 34 DECEMBER 1, 2016 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the
More information/ NCCN. ACS (www.cancer.org) NCC (www.nccn.org) NCCN NCCN ACS ACS-2345
/2002 9 /2002 9 (NCCN) (ACS) NCCN ACS (www.cancer.org) NCC (www.nccn.org) NCCN 1-888-909-NCCN ACS 1-800-ACS-2345 NCCN ACS NCCN NCCN ACS NCCN 2002 (NCCN) (ACS) NCCN ACS ...................................
More informationDeveloping evidence: the value of family health history. Lori A. Orlando, MD MHS
Developing evidence: the value of family health history Lori A. Orlando, MD MHS Family Health History Nominally the first genetic test (Francis Collins) Reflects both: Shared environments Shared genetics
More informationPage 1 of 5 Home > Research & Grants > Research and Scientific Programs > What is genetic testing for breast cancer and who should get it? What is genetic testing for breast cancer and who should get it?
More informationOvarian Cancer Conference
Memorial Sloan Kettering Cancer Center is pleased to announce: State of the Art Ovarian Cancer Conference Thursday, October 6, 2016 www.mskcc.org/ovarianconference Course Overview Advances in women s health
More informationFIELD NOTES. Chris Anderson our Senior Editor gives a roundup of the recent developments in the precision medicine field.
FIELD NOTES Chris Anderson our Senior Editor gives a roundup of the recent developments in the precision medicine field. QIAGEN on behalf of the Allele Frequency community Adding value to allele data REDWOOD
More informationClinical Genome Knowledge Base and Linked Data technologies. Aleksandar Milosavljevic
Clinical Genome Knowledge Base and Linked Data technologies Aleksandar Milosavljevic Topics 1. ClinGen Resource project 2. Building the Clinical Genome Knowledge Base 3. Linked Data technologies 4. Using
More informationPeter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective
第 53 回日本癌治療学会学術集会 ASCO, ESMO, ECCO からの招聘演者と講演予定 Peter P. Yu (President of American Society of Clinical Oncology, ASCO) Collaboration between ASCO and JSCO: Future Perspective Ralf A. Stahel (President
More informationOvarian Cancers: Evolving Paradigms in Research and Care Report Release Wednesday, March 2, 2016
Ovarian Cancers: Evolving Paradigms in Research and Care Report Release Wednesday, March 2, 2016 Committee Membership Jerome F. Strauss, III, (Chair), Virginia Commonwealth University School of Medicine
More informationImplementation Guide Working Group Members
Establishing Connectivity and Clinical Decision Support Rules for Patients Carrying MLH1, MSH2, MSH6, and PMS2 (Lynch Syndrome) Variants An Implementation Guide 14 August 2017 CSER EHR Working Group Version
More informationScience Report ADVANCES IN CANCER RESEARCH
Science Report ADVANCES IN CANCER RESEARCH Created by Huntsman Cancer Institute s Office of Communications 2016 www.huntsmancancer.org OUR TIME BEGAN with an empty lot and a dream full of promise, determination,
More informationThe Cancer Genome Atlas Project Overview
TheCancerGenomeAtlasProjectOverview InSeptember2006,TheCancerGenomeAtlas(TCGA)programannouncedplanstomap genomicchangesoflung,brainandovariancancertumorsusinglargescalesequencing technologies. Seven institutions
More informationModelling cancer risk predictions:clinical practice perspective.
Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult
More informationBreast cancer risk prediction using a polygenic risk score in the familial setting: a
Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kconfab Hongyan Li 1 MSc, Bingjian Feng 2 PhD, Alexander
More informationCancer Treatment and Research
Cancer Treatment and Research Volume 155 Series Editor Steven T. Rosen For further volumes: http://www.springer.com/series/5808 Boris Pasche Editor Cancer Genetics 123 Editor Boris Pasche, MD, PhD, FACP
More informationTamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study Steven A Narod, Jean-Sébastien Brunet, Parviz Ghadirian, Mark Robson, Ketil Heimdal, Susan L
More informationAdvances in Breast Cancer Research: Genetics, Biology, and Clinical Applications
An AACR Special Conference on October 12-15, 2011 The Fairmont San Francisco San Francisco, CA Wednesday, October 12 7:00 p.m.-8:00 p.m. Opening Keynote Address Chairperson: Jeffrey M. Rosen, Baylor College
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More informationImpressions of a New NCI Director: Big Data
Impressions of a New NCI Director: Big Data Norman E. Sharpless, M.D. Cancer Informatics for Cancer Centers April 3, 2018 www.cancer.gov www.cancer.gov/espanol October 17, 2018 NCI: Leading the National
More informationGenetic Susceptibility to Cancer the GWAS era. Program in Genetic Epidemiology i and Statistical. Channing Laboratory, Brigham and Women s Hospital
Genetic Susceptibility to Cancer the GWAS era David Hunter Program in Genetic Epidemiology i and Statistical ti ti Genetics Harvard School of Public Health Channing Laboratory, Brigham and Women s Hospital
More informationRESULTS. rs and rs are associated with survival after adjuvant chemotherapy
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 6, No. 10 The SNP rs6500843 in 16p13.3 is associated with survival V S H F L F D O O \ D P R Q J F K H P R W K H U D S \ W U H D W H G E U H D V W F
More informationBRCA1 MUTATIONS IN WOMEN ATTENDING CLINICS THAT EVALUATE THE RISK OF BREAST CANCER
BRCA1 MUTATIONS IN WOMEN ATTENDING CLINICS THAT EVALUATE THE RISK OF BREAST CANCER FERGUS J. COUCH, PH.D., MICHELLE L. DESHANO, B.S., M. ANNE BLACKWOOD, M.D., KATHLEEN CALZONE, B.S.N., R.N., JILL STOPFER,
More informationTwenty-One Gene Recurrence Score Assay in BRCA-Associated Versus Sporadic Breast Cancers: Differences Based on Germline Mutation Status
Twenty-One Gene Recurrence Score Assay in BRCA-Associated Versus Sporadic Breast Cancers: Differences Based on Germline Mutation Status Payal D. Shah, MD 1 ; Sujata Patil, PhD 2 ; Maura N. Dickler, MD
More informationTranslation of Genomics for Patient Care and Research: The Clinical End-User
Translation of Genomics for Patient Care and Research: The Clinical End-User Jason L. Vassy, MD, MPH, SM Harvard Medical School, Brigham and Women s Hospital, and VA Boston Healthcare System Institute
More informationInterpretation can t happen in isolation. Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill
Interpretation can t happen in isolation Jonathan S. Berg, MD/PhD Assistant Professor Department of Genetics UNC Chapel Hill With the advent of genome-scale sequencing, variant interpretation is increasingly
More informationCancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023
Cancer Immunotherapy Artificial Intelligence: Market Shares, Strategies, and Forecasts, 2017 to 2023 Table of Contents Cancer Immunotherapy Artificial Intelligence: Executive Summary The study is designed
More informationLaunching PCORnet, the National Patient- Centered Clinical Research Network
Launching PCORnet, the National Patient- Centered Clinical Research Network Rachael L. Fleurence, PhD February 25th, 2014 1 PCORnet 2 PCORnet: the National Patient-Centered Clinical Research Network The
More informationDONNA BOWERS & ALAN MILLER
BAYLOR HEALTH CARE SYSTEM ONCOLOGY NETWORK NEWS UPDATE WITH YOUR BHCS ONCOLOGY ANCHORS DONNA BOWERS & ALAN MILLER 1 The Evolution of Cancer Care Slash, burn and poison era Precision Medicine Casting out
More informationNorth East Partnership Board Meeting
North East Partnership Board Meeting 29 th January Sunderland Welcome and Introductions The meeting was chaired by Jodie Williams and Lesley Jeavons. We went around the room and everyone said who they
More informationGenomics in Public Health
Genomics in Public Health Cascade Screening Working Group Leadership Meeting Heather Hampel Katherine Wilemon Co-chairs; GPHAC March 19, 2018 Cascade Screening Working Group Vision Identify gaps in research
More informationGeisinger s Precision Health Initiative
Geisinger s Precision Health Initiative June 28, 2017 David H. Ledbetter, PhD, FACMG Geisinger Health System dhledbetter@geisinger.edu 1 3.5% Expected to get results 8,700+ Participants MyCode Footprint
More informationPROPOSED WORK PROGRAMME FOR THE CLEARING-HOUSE MECHANISM IN SUPPORT OF THE STRATEGIC PLAN FOR BIODIVERSITY Note by the Executive Secretary
CBD Distr. GENERAL UNEP/CBD/COP/11/31 30 July 2012 ORIGINAL: ENGLISH CONFERENCE OF THE PARTIES TO THE CONVENTION ON BIOLOGICAL DIVERSITY Eleventh meeting Hyderabad, India, 8 19 October 2012 Item 3.2 of
More informationBreast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS
Breast and ovarian cancer in Serbia: the importance of mutation detection in hereditary predisposition genes using NGS dr sc. Ana Krivokuća Laboratory for molecular genetics Institute for Oncology and
More informationLarge-scale identity-by-descent mapping discovers rare haplotypes of large effect. Suyash Shringarpure 23andMe, Inc. ASHG 2017
Large-scale identity-by-descent mapping discovers rare haplotypes of large effect Suyash Shringarpure 23andMe, Inc. ASHG 2017 1 Why care about rare variants of large effect? Months from randomization 2
More informationALBERTA PRINCIPAL INVESTIGATORS
ALBERTA PRINCIPAL INVESTIGATORS Dr. Gregory Cairncross is Head of the Department of Clinical Neurosciences at the University of Calgary and holder of the Alberta Cancer Foundation Chair in Brain Tumor
More informationSelecting the right genes to report in newborn genomic sequencing: The BabySeq Project
Selecting the right genes to report in newborn genomic sequencing: The BabySeq Project Ozge Ceyhan Birsoy, Ph.D. Partners HealthCare Laboratory for Molecular Medicine Broad Institute Clinical Research
More informationThe Genie Is Out of the Bottle. Richard E. Ya Deau, MD FACS, FACHCE (HON)
The Genie Is Out of the Bottle Richard E. Ya Deau, MD FACS, FACHCE (HON) Participatory Research 23andme Your genetic data Richard YaDeau Genes vs. Environment 60-80 % Attributable to Genetics The heritability
More informationThe New England Journal of Medicine ORAL CONTRACEPTIVES AND THE RISK OF HEREDITARY OVARIAN CANCER. Subjects
ORAL CONTRACEPTIVES AND THE RISK OF HEREDITARY OVARIAN CANCER STEVEN A. NAROD, M.D., HARVEY RISCH, M.D., PH.D., ROXANA MOSLEHI, M.SC., ANNE DØRUM, M.D., SUSAN NEUHAUSEN, PH.D., HAKAN OLSSON, M.D., DIANE
More information4th Central Eastern European Symposium on Free Nucleic Acids in Non-Invasive Prenatal Diagnosis Split, May Second Announcement
Josip Juraj Strossmayer University of Osijek FACULTY OF MEDICINE OSIJEK 4th Central Eastern European Symposium on Free Nucleic Acids in Non-Invasive Prenatal Diagnosis Split, 25-26 May 2016 Second Announcement
More informationThe Terry Fox Pan-Canadian Enhanced Pancreatic Cancer Profiling for Individualized Care (EPPIC) Project 19 Sep :00am-5:30pm
TFRI Pancreatic Cancer Workshop Project Name: Date: The Terry Fox Pan-Canadian Enhanced Pancreatic Cancer Profiling for Individualized Care (EPPIC) Project 19 Sep 2015 9:00am-5:30pm Location: Sheraton
More informationGenomics in Public Health Vision and Goals for the Population Screening Working Group
Genomics in Public Health Vision and Goals for the Population Screening Working Group Mike Murray Jim Evans Co-chairs; IOM Action Collaborative 24 February 2017 Washington DC Intent of IOM Action Collaborative
More informationThe Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine
The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection
More informationNo Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers
Hereditary Cancer in Clinical Practice 2007; 5(2) pp. 67-71 No Sib Pair Concordance for Breast or Ovarian Cancer in BRCA1 Mutation Carriers Pål Møller 1, Lovise Mºhle 1, Neal Clark 1, Jaran Apold 2 1 Section
More informationCYPRESS U CRITICAL UPDATE
CYPRESS U CRITICAL UPDATE CASE STUDIES IN CANCER CARE MANAGEMENT John Van Dyke, Interlink Copyright INTERLINK Care Management, Inc. 2014 Presented by: John Van Dyke Chief Executive Officer INTERLINK COE
More informationClinical Decision Support Technologies for Oncologic Imaging
Clinical Decision Support Technologies for Oncologic Imaging Ramin Khorasani, MD, MPH Professor of Radiology Harvard Medical School Distinguished Chair, Medical Informatics Vice Chair, Department of Radiology
More informationA future where everybody who develops breast cancer lives and lives well. Our vision, mission, values and five-year strategy ( )
A future where everybody who develops breast cancer lives and lives well Our vision, mission, values and five-year strategy (2017 2022) Welcome We are delighted to present Breast Cancer Now s new long-term
More informationP NK. Breast Cancer Genetic Risk Test. Test Report
Test Report CONTENTS SECTION 1 1-1. Patient Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Genes Tested SECTION 2 2-1. About the Test 2-2. References 1-1. Patient Information
More informationOpportunity and Challenge
Opportunity and Challenge Implementation of Comparative Effectiveness Research: The Patient Protection and Affordable Care Act Dr. Ellen V. Sigal, Chair & Founder, Friends of Cancer Research Comparative
More informationProgress Update June 2017 Lay Summary Funding: $6,000,000 Grant Funded: July 2015 Dream Team Members Dream Team Leader:
SU2C -Ovarian Cancer Research Fund Alliance-National Ovarian Cancer Coalition Dream Team Translational Research Grant: DNA Repair Therapies for Ovarian Cancer AND SU2C Catalyst Merck-Supported Supplemental
More informationSession 1 Clinical Manifestations of Cancer Cachexia (Chair: Aminah Jatoi, MD)
Cancer Cachexia: Molecular Mechanisms and Therapeutic Approaches Boston, September 21-23, 2012 Friday, September 21, 2012 1:00 pm Registration and Poster Set-up Foyer Maverick A&B 4:00-4:10 pm Introductory
More informationConsensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer
Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer Purpose: To outline an approach to hereditary cancer genetic testing for patients with and without breast cancer
More informationRisk-reducing Surgery in BRCA mutation carriers
Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS Overview of HBOC
More informationOHSU Moore Institute for Nutrition & Wellness OHSU School of Medicine. Diane Stadler, PhD, RD Graduate Programs in Human Nutrition
OHSU Moore Institute for Nutrition & Wellness OHSU School of Medicine Diane Stadler, PhD, RD Graduate Programs in Human Nutrition Moore Institute for Nutrition & Wellness There is no question that a nutritious,
More informationWhen the question is genetics, the answer is Invitae Invitae Corporation. All Rights Reserved. 1
When the question is genetics, the answer is Invitae. L A D E N B U R G T H A L M A N N 2 0 1 8 H E A LT H C A R E C O N F E R E N C E S E A N G E O R G E, C H I E F E X E C U T I V E O F F I C E R 2018
More informationATHENA WISDOM INITIATIVE: RISK-BASED SCREENING FOR BREAST CANCER
ATHENA WISDOM INITIATIVE: RISK-BASED SCREENING FOR BREAST CANCER The Screening Debate in the US? ACS vs. USPSTF When to start, when to stop, screening intervals, modality] Little guidance around operationalizing
More informationConsent for Revealing Biomarker Status in AD Prevention Trials
Consent for Revealing Biomarker Status in AD Prevention Trials J. Scott Roberts, PhD Associate Professor Department of Health Behavior & Health Education University of Michigan School of Public Health
More informationSATURDAY, NOVEMBER 4, :00 AM 4:30 PM
Virginia Oncology Associates 18 th Annual Conference NEW DEVELOPMENTS IN ONCOLOGY Addressing Novel Therapies In Oncology & Hematology SATURDAY, NOVEMBER 4, 2017 7:00 AM 4:30 PM Hilton Virginia Beach Oceanfront
More informationPALB2 c g>c is. VARIANT OF UNCERTAIN SIGNIFICANCE (VUS) CGI s summary of the available evidence is in Appendices A-C.
Consultation sponsor (may not be the patient): First LastName [Patient identity withheld] Date received by CGI: 2 Sept 2017 Variant Fact Checker Report ID: 0000001.5 Date Variant Fact Checker issued: 12
More informationAdding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants
RESEARCH ARTICLE Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants OFFICIAL JOURNAL www.hgvs.org Maxime P. Vallée, 1 Tonya L. Di
More informationVI. Ovarian Cancer Research Program
VI. Ovarian Cancer Program Vision: To eliminate ovarian cancer. Mission: To support innovative, integrated, multidisciplinary research efforts that will lead to a better understanding, detection, diagnosis,
More informationAssociation of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality JAMA. 2010;304(9):
ORIGINAL CONTRIBUTION Association of Risk-Reducing Surgery in or Mutation Carriers With Cancer Risk and Mortality Susan M. Domchek, MD Tara M. Friebel, MPH Christian F. Singer, MD, MPH D. Gareth Evans,
More informationProgram of Mental Health Research, QIMR Berghofer
Program of Mental Health Research, QIMR Berghofer Michael Breakspear Coordinator, Program of Mental Health, QIMR Berghofer Psychiatrist, Brisbane Women s Correctional Centre Chair, Metro North Research
More informationNational Efforts towards Standardizing Variant Interpretation (ClinGen)
National Efforts towards Standardizing Variant Interpretation (ClinGen) Andy Faucett, MS, CGC Kelly Ormond, MS, CGC http://clinicalgenome.org/ Conflict of Interest Disclosures In relation to this presentation,
More informationSurveillance and SEER Where are we going? NAACCR Meeting June 23, 2017 Lynne Penberthy MD, MPH
Surveillance and SEER Where are we going? NAACCR Meeting June 23, 2017 Lynne Penberthy MD, MPH Presentation Objectives Describe Future Role of Registries & Registrars Challenges to cancer surveillance
More informationGeorgia Cancer Quality Information Exchange
Georgia Cancer Quality Information Exchange Measuring Progress, Motivating Change William J. Todd President & Chief Executive Officer October 5, 2009 Hamilton Jordan 1944 2008 Georgia Cancer Coalition
More informationBreast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou
Breast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou Department of Public Health and Primary Care University of Cambridge, U.K. Cancer risk prediction in the era
More informationUPDATES IN OVARIAN CANCER RESEARCH
UPDATES IN OVARIAN CANCER RESEARCH WHAT IS OVARIAN CANCER? The ovaries are two small oval organs, each about 2 4cm across, that sit on either side of the uterus and produce eggs (ova). The ovaries also
More informationKnowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains
Knowledge networks of biological and medical data An exhaustive and flexible solution to model life sciences domains Dr. Sascha Losko, Dr. Karsten Wenger, Dr. Wenzel Kalus, Dr. Andrea Ramge, Dr. Jens Wiehler,
More informationVariant Classification: ACMG recommendations. Andreas Laner MGZ München
Variant Classification: ACMG recommendations Andreas Laner MGZ München laner@mgz-muenchen.de OVERVIEW Introduction ACMG-AMP Classification System Evaluation of inter-laboratory concordance in variant classification
More informationIDENTIFICATION AND MOLECULAR ANALYSES OF FAMILIES WITH SUSCEPTIBILITY TO BREAST AND/OR OVARIAN CANCER MREC/01/2/18 PROTOCOL VERSION 3 JUNE 2012
IDENTIFICATION AND MOLECULAR ANALYSES OF FAMILIES WITH SUSCEPTIBILITY TO BREAST AND/OR OVARIAN CANCER MREC/01/2/18 PROTOCOL VERSION 3 JUNE 2012 SUMMARY Purpose The programme has four overarching aims:
More information6:00 p.m.-7:00 p.m. Opening Keynote Address Salons EF
THURSDAY, OCTOBER 20 6:00 p.m.-7:00 p.m. Opening Keynote Address 6:00 p.m.-7:00 p.m. Title to be announced Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA 7:00
More informationConsensus Guideline on Genetic Testing for Hereditary Breast Cancer
Consensus Guideline on Genetic Testing for Hereditary Breast Cancer Purpose: To outline recommendations for genetic testing that medical professionals can use to assess hereditary risk for breast cancer
More informationTITLE: Aurora-A as a Modifier of Breast Cancer Risk in BRCA1/2 Mutation Carriers
AD Award Number: W81XWH-04-1-0588 TITLE: Aurora-A as a Modifier of Breast Cancer Risk in BRCA1/2 Mutation Carriers PRINCIPAL INVESTIGATOR: Fergus J. Couch, Ph.D. CONTRACTING ORGANIZATION: Mayo Clinic Rochester,
More informationSWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology
SWOG Plenary I Translational Medicine Science as the Foundation for Rapid and Meaningful Advances in Oncology Lee M. Ellis, MD SWOG Vice Chair, Translational Medicine Departments of Surgical Oncology and
More informationLIVESTRONG Patient Navigation Services Program (PNSP)
Lance Armstrong Foundation LIVESTRONG Patient Navigation Services Program (PNSP) Caroline Huffman, LCSW, M.Ed. Navigation Landscape Patient Navigation Center at Ralph Lauren Center Dr Freeman s model American
More informationDay 0 Sunday, July 8: Arrivals. Day 1 Monday, July 9: Introduction, Fundamentals, and Germline Variation. *As of 6/29/18
AACR Integrative Molecular Epidemiology Workshop: Bridging Cancer Biology and Precision Medicine July 9-13, 2018 (*arrival July 8) Westin Copley Place, Boston Boston, Massachusetts *As of 6/29/18 Director:
More information8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina
FIRST ANNOUNCEMENT 8 th InterAmerican Oncology Conference 'Current Status and Future of Anti-Cancer Targeted Therapies' October 17-18, 2019 Buenos Aires, Argentina The 8 th Conference of IAOC "Current
More informationDementia Friendly Communities Recognition Process. Karishma Chandaria Dementia Friendly Communities Programme Manager
Dementia Friendly Communities Recognition Process Karishma Chandaria Dementia Friendly Communities Programme Manager Living well with dementia Development of DFCs Progress in creating dementia friendly
More informationNotes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to fina
Notes for slide 2 Welcome to today s training webinar. We appreciate everyone taking time today to hear our presentations. We are very excited to finally be able to put these genomics related data items
More informationSunday, March 13th (Day Zero) NCI-ITCR Workshop. 10:00 AM Spring 2016 Conference Symposium Chairs Kickoff: Warren Kibbe & Sorena Nadaf
From Towards Precision Medicine To A Cancer Moonshot Building a Learning Healthcare System For Cancer Research and Care Sunday, March 13th (Day Zero) NCI-ITCR Workshop National Cancer Institute Informatics
More informationConference Program. 1:30 p.m.-2:30 p.m. Mining the TCGA Douglas A. Levine, Memorial Sloan-Kettering Cancer Center, New York, NY
Wednesday, September 18 Conference Program 11:00 a.m.-9:00 p.m. Registration Open 1:30 p.m.-5:50 p.m. Educational Session 1:30 p.m.-2:30 p.m. Mining the TCGA Douglas A. Levine, Memorial Sloan-Kettering
More informationPROGRAM. Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada
Thursday, May 4 Educational Session: Genomics 15:00-17:00 Session Chair: Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada Molecular Tumor Board - Case Presentation Lillian L. Siu, Patricio
More information